Print this page    •   Back to Web version of article

Maraviroc Approved for First-Line Therapy

By Liz Highleyman

Winter/Spring 2010

In late November, the U.S. Food and Drug Administration (FDA) approved the first CCR5 antagonist, maraviroc (Selzentry), for treatment-naive individuals with exclusively CCR5-tropic virus (determined using the Trofile assay). Given the first-line approval of the first integrase inhibitor, raltegravir, this past July, people starting ART now have a wider array of effective and well-tolerated options.

The MERIT trial initially suggested that maraviroc did not work quite as well as efavirenz (Sustiva) for treatment-naive people with high viral load, but an analysis using the current, more sensitive Trofile assay found that the two drugs worked equally well after excluding participants originally misclassified as having only CCR5-tropic virus. Maraviroc is well-tolerated overall, and recent studies suggest that it may produce larger CD4 cell gains and reduce inflammation more than drugs from other classes (see "Inflammation, Immune Activation, and HIV").

Liz Highleyman (liz@black-rose.com) is a freelance medical writer based in San Francisco.




This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art58348.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.